Search Results for: hiv prognosis
Researchers open ‘Pandora’s box’ of potential cancer biomarkers
ANN ARBOR, Mich. — A new analysis opens the door to discovery of thousands of potential new cancer biomarkers.
Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of a portion of the genome that has not been previously well-explored - long non-coding RNAs. This vast portion of the human genome has been considered the dark matter because so little is known about it. Emerging new evidence suggests that lncRNAs may play a role in cancer and that understanding them better could lead to new potential targets for improving cancer diagnosis, prognosis or treatment.
“We know about protein-coding genes, but that represents only 1-2 percent of the genome. Much less is known about the biology of the non-coding genome in terms of how it might function in a human disease like cancer,” says senior study author Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at the University of Michigan Medical School.
Incoming search terms:
- arul chinnaiyan michigan database
- mitranscriptome
- what is the eighty percent of unexplored human dna
- what percentage of the human genome is made up of protein encoding genes
THERADIAG strengthens its microRNA development program, adds lncRNA research program
Croissy-Beaubourg and Montpellier, January 20, 2024 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, has signed, through its subsidiary Prestizia, two partnership agreements for the development of theranostics assays in HIV/AIDS with the research teams of the French National Center for Scientific Research (CNRS) / Institute of Molecular Genetics of Montpellier (IGMM) and the University of Montpellier (UM2).
“By strengthening its collaboration with CNRS on microRNAs, and extending it to lncRNAs, Theradiag is now at the forefront of research and development of new diagnostics and monitoring tools for HIV/AIDS,” comments Odile Prigneau, Managing Director of Prestizia.
The purpose of the first agreement is to implement two of the four theranostics projects part of CaReNA, a collaborative project between Theradiag, Splicos and CNRS signed in 2013 and funded by OSEO[1]. These two theranostics projects are:
Incoming search terms:
- hiv prognosis